High Performance Antigen Diagnostics
Key Takeaways
- Set-aside for No Set Aside businesses
- Work to be performed in Washington, DC
- Industry: Research and Development in Biotechnology (except Nanobiotechnology)
- This is market research - no award at this stage
Contract Details
- Notice ID
- RRPV-HPAD
- Opportunity Type
- Sources Sought
- Sub-Agency
- OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
- Office
- ASPR BARDA DIV CONTRACTS MGMT & ACQ
- Posted Date
- Wednesday, June 17, 2026
- Response Deadline
- Friday, July 17, 2026
- PSC Code
- AN13
- Set-Aside
- No Set Aside
- Place of Performance
- Washington, DC, 20515
- Status
- Active
Description
High Performance Antigen Diagnostics Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.
Why This Opportunity Matters
HEALTH AND HUMAN SERVICES, DEPARTMENT OF is conducting market research to identify potential sources for research and development in biotechnology (except nanobiotechnology) with a set-aside for No Set Aside businesses in Washington, DC. Responding to this notice helps ensure your company is considered for the eventual solicitation.
Similar Opportunities
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
- Knowledge Base
- Guides
- Glossary
- Q&A
- Documentation
- Blog
- For Small Business
- For Capture Teams
- Compare Platforms
- Services
- Workflow Automation
- Support
- Contact Us